Adjuvant aspirin therapy and colorectal cancer survival

Affiliations

¹ Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.
² Departments of Epidemiology and Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA; Clinical and Translational Epidemiology Unit and Division of Gastroenterology, Massachusetts General Hospital, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA. Electronic address: msong@hsph.harvard.edu.

Comment

Seohyuk Lee et al. Lancet Gastroenterol Hepatol. 2025 Mar.

. 2025 Mar;10(3):184-185.

doi: 10.1016/S2468-1253(24)00393-5. Epub 2025 Jan 14.

¹ Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.
² Departments of Epidemiology and Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA; Clinical and Translational Epidemiology Unit and Division of Gastroenterology, Massachusetts General Hospital, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA. Electronic address: msong@hsph.harvard.edu.

No abstract available

Conflict of interest statement

We declare no competing interests.

Aspirin after completion of standard adjuvant therapy for colorectal cancer (ASCOLT): an international, multicentre, phase 3, randomised, double-blind, placebo-controlled trial.
Chia JWK, Segelov E, Deng Y, Ho GF, Wang W, Han S, Sharma A, Ding K, Chen G, Jeffery MG, Tham CK, Ahn JB, Nott L, Zielinski R, Chao TY, van Hagen T, Wei PL, Day F, Mehta S, Yau T, Peng J, Hayes TM, Li Y, Gandhi M, Foo EMJ, Rahman N, Rothwell P, Ali R, Simes J, Toh HC. Chia JWK, et al. Lancet Gastroenterol Hepatol. 2025 Mar;10(3):198-209. doi: 10.1016/S2468-1253(24)00387-X. Epub 2025 Jan 14. Lancet Gastroenterol Hepatol. 2025. PMID: 39824200 Clinical Trial.